Chronic Kidney Disease Explained: Stages, Causes, and Management

37 Million Americans Have Kidney Disease — 90% Don't Know It

Chronic kidney disease (CKD) affects approximately 37 million Americans — about 15% of the adult population. The National Kidney Foundation estimates that 9 out of 10 people with CKD are undiagnosed because the condition produces no symptoms until substantial kidney function has already been lost. The kidneys perform functions so essential — filtering waste, regulating fluid balance, controlling blood pressure, producing hormones for red blood cell production — that their silent failure over years eventually reaches a crisis point that might have been managed or delayed with earlier detection.

What the Kidneys Actually Do

Each kidney contains approximately 1 million nephrons — the functional filtering units. Blood passes through each nephron's glomerulus (a tiny capillary cluster), where waste products and excess water are filtered from the blood and excreted as urine, while essential substances are reabsorbed. Beyond filtration, the kidneys:

• Regulate blood pressure through the renin-angiotensin-aldosterone system
• Produce erythropoietin (EPO), which stimulates red blood cell production in bone marrow
• Activate vitamin D (essential for bone health and calcium absorption)
• Maintain acid-base balance in the blood
• Regulate electrolyte levels (sodium, potassium, phosphate)

When nephrons are damaged, they don't regenerate. Remaining nephrons compensate — enlarging and working harder — but progressive loss eventually overwhelms this compensation.

The Five Stages of CKD

GFR (glomerular filtration rate) is estimated through a blood test measuring creatinine — a waste product normally cleared by the kidneys. As kidney function declines, creatinine accumulates in the blood, lowering the estimated GFR. Urinary albumin (protein in urine, called albuminuria or proteinuria) is the other key marker — its presence indicates kidney damage even when GFR remains normal.

Common Causes

Two conditions cause more than half of all CKD cases:

• Diabetes (diabetic nephropathy): The leading cause of kidney failure in the US. High blood glucose damages the glomerular filtration membrane over years. Diabetic nephropathy is largely preventable with tight blood glucose control and blood pressure management.
• Hypertension (hypertensive nephropathy): The second leading cause. High blood pressure damages kidney blood vessels and, over time, reduces filtering capacity.

Other causes include:

• Glomerulonephritis (immune-mediated kidney damage) — a leading cause in younger patients
• Polycystic kidney disease (genetic; progressive cyst growth destroys normal tissue)
• Repeated urinary tract infections or obstruction
• Prolonged use of NSAIDs (ibuprofen, naproxen) — particularly damaging to kidneys already under stress
• Contrast dye used in imaging studies (more problematic in those with reduced GFR)

Symptoms: The Problem of Silence

Early CKD is typically asymptomatic. Symptoms that do appear are often nonspecific:

• Fatigue and weakness (from anemia — kidneys produce less EPO)
• Decreased urine output or foamy urine (proteinuria)
• Swelling in legs, ankles, and feet (fluid retention)
• Hypertension that's difficult to control
• Itching (from waste product accumulation)

Advanced CKD produces uremic symptoms — nausea, confusion, shortness of breath, and severe fluid overload — at which point dialysis or transplantation becomes urgent.

Management Strategies

• Blood pressure control: Target under 130/80 mmHg. ACE inhibitors and ARBs are first-line; they reduce proteinuria independently of blood pressure effects.
• Blood glucose control: In diabetic patients, target HbA1c typically under 7%. SGLT-2 inhibitors (empagliflozin, canagliflozin) have demonstrated kidney-protective effects beyond glucose control in CKD clinical trials.
• Dietary modification: Low-sodium diet for blood pressure; protein moderation (but not elimination) reduces nitrogen waste load; phosphate restriction in advanced stages to protect bone health; potassium restriction when levels are elevated.
• Anemia management: EPO-stimulating agents (ESAs) + iron supplementation when hemoglobin falls below treatment thresholds.
• Medication review: Many medications are dose-adjusted or avoided entirely in CKD — including metformin, many antibiotics, and contrast agents.

Dialysis Options

Kidney transplantation, when successful, offers the best long-term outcomes compared to dialysis — better quality of life, longer survival, and freedom from dialysis schedules. The waiting list for a deceased donor kidney averages 3–5 years; living donor transplantation dramatically reduces waiting time.

Disclaimer: This article is for educational purposes only. CKD management requires individualized medical care from a nephrologist and primary care team. Do not make medication or dietary changes without medical supervision.